{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:27:32Z","timestamp":1791779252791,"version":"4.3.4"},"reference-count":42,"publisher":"Baishideng Publishing Group Inc.","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2009]]},"DOI":"10.3748\/wjg.15.2731","type":"journal-article","created":{"date-parts":[[2009,6,13]],"date-time":"2009-06-13T02:45:05Z","timestamp":1244861105000},"page":"2731","source":"Crossref","is-referenced-by-count":34,"title":["Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions"],"prefix":"10.3748","volume":"15","author":[{"given":"Li-Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Long","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Kun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Cheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Sheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Ren","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.","DOI":"10.1002\/ijc.1440"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-1791.","DOI":"10.1093\/jnci\/djg106"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology 1997;113:S56-S60.","DOI":"10.1016\/S0016-5085(97)80013-3"},{"key":"ref4","unstructured":"Konturek PC, Konturek SJ, Brzozowski T. Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol 2006;57 Suppl 3:51-65."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Arber N, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 2008;134:1224-1237.","DOI":"10.1053\/j.gastro.2008.02.012"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999;94:1218-1223.","DOI":"10.1111\/j.1572-0241.1999.01070.x"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK, Chan FK. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157:729-735.","DOI":"10.1016\/S0002-9440(10)64586-5"},{"key":"ref8","unstructured":"Sheu BS, Yang HB, Sheu SM, Huang AH, Wu JJ. Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin Cancer Res 2003;9:5245-5251."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Nardone G, Rocco A. Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents. Dig Dis 2004;22:320-326.","DOI":"10.1159\/000083593"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Dai Y, Wang WH. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol 2006;12:2884-2889.","DOI":"10.3748\/wjg.v12.i18.2884"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.","DOI":"10.1097\/00000478-199610000-00001"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Yu J, Hui AY, Chu ES, Cheng AS, Go MY, Chan HL, Leung WK, Cheung KF, Ching AK, Chui YL. Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis. Gut 2007;56:991-999.","DOI":"10.1136\/gut.2006.097923"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJ, Offerhaus GJ, Ristimaki A. Cyclooxygenase-2 and gastric carcinogenesis. APMIS 2003;111:915-925.","DOI":"10.1034\/j.1600-0463.2003.1111001.x"},{"key":"ref14","unstructured":"Saukkonen K, Nieminen O, van Rees B, Vilkki S, Härkönen M, Juhola M, Mecklin JP, Sipponen P, Ristimäki A. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res 2001;7:1923-1931."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Rocco A, Caruso R, Toracchio S, Rigoli L, Verginelli F, Catalano T, Neri M, Curia MC, Ottini L, Agnese V. Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression. Ann Oncol 2006;17 Suppl 7:vii103-vii108.","DOI":"10.1093\/annonc\/mdl961"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"van Rees BP, Saukkonen K, Ristimäki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002;196:171-179.","DOI":"10.1002\/path.1033"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Xiao F, Furuta T, Takashima M, Shirai N, Hanai H. Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL\/6 mice. Aliment Pharmacol Ther 2001;15:875-886.","DOI":"10.1046\/j.1365-2036.2001.00965.x"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Kim TI, Lee YC, Lee KH, Han JH, Chon CY, Moon YM, Kang JK, Park IS. Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity. Infect Immun 2001;69:5056-5063.","DOI":"10.1128\/IAI.69.8.5056-5063.2001"},{"key":"ref19","unstructured":"Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimäki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res 2003;63:3032-3036."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Hahm KB, Song YJ, Oh TY, Lee JS, Surh YJ, Kim YB, Yoo BM, Kim JH, Han SU, Nahm KT. Chemoprevention of Helicobacter pylori-associated gastric carcinogenesis in a mouse model: is it possible? J Biochem Mol Biol 2003;36:82-94.","DOI":"10.5483\/BMBRep.2003.36.1.082"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nam KT, Hahm KB, Oh SY, Yeo M, Han SU, Ahn B, Kim YB, Kang JS, Jang DD, Yang KH. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin Cancer Res 2004;10:8105-8113.","DOI":"10.1158\/1078-0432.CCR-04-0896"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Futagami S, Suzuki K, Hiratsuka T, Shindo T, Hamamoto T, Tatsuguchi A, Ueki N, Shinji Y, Kusunoki M, Wada K. Celecoxib inhibits Cdx2 expression and prevents gastric cancer in Helicobacter pylori-infected Mongolian gerbils. Digestion 2006;74:187-198.","DOI":"10.1159\/000100503"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Zhu GH, Yang XL, Lai KC, Ching CK, Wong BC, Yuen ST, Ho J, Lam SK. Nonsteroidal antiinflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells. Dig Dis Sci 1998;43:1957-1963.","DOI":"10.1023\/A:1018830408397"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AH, Sung JJ. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200.","DOI":"10.1136\/gut.2003.021477"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Yu J, Tang BD, Leung WK, To KF, Bai AH, Zeng ZR, Ma PK, Go MY, Hu PJ, Sung JJ. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention. World J Gastroenterol 2005;11:41-45.","DOI":"10.3748\/wjg.v11.i1.41"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci 2008;65:1295-1301.","DOI":"10.1007\/s00018-008-7511-x"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Andrews J, Djakiew D, Krygier S, Andrews P. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 2002;50:277-284.","DOI":"10.1007\/s00280-002-0485-8"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-9258.","DOI":"10.1038\/sj.onc.1208169"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"I\u00f1iguez MA, Rodríguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003;9:73-78.","DOI":"10.1016\/S1471-4914(02)00011-4"},{"key":"ref30","unstructured":"Honjo S, Kase S, Osaki M, Ardyanto TD, Kaibara N, Ito H. Cyclooxygenase-2 expression in human gastric tubular adenomas and carcinomas; correlation with intratumoral microvessel density and apoptotic index. Anticancer Res 2004;24:1439-1444."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Tatsuguchi A, Matsui K, Shinji Y, Gudis K, Tsukui T, Kishida T, Fukuda Y, Sugisaki Y, Tokunaga A, Tajiri T. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 2004;35:488-495.","DOI":"10.1016\/j.humpath.2003.10.025"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-747.","DOI":"10.1093\/jnci\/djj206"},{"key":"ref33","unstructured":"Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-1477."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Wu YL, Fu SL, Zhang YP, Qiao MM, Chen Y. Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts. Biomed Pharmacother 2005;59 Suppl 2:S289-S292.","DOI":"10.1016\/S0753-3322(05)80048-4"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Han S, Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs 2007;18:237-244.","DOI":"10.1097\/CAD.0b013e328011e67d"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Konturek PC, Konturek SJ, Bielanski W, Kania J, Zuchowicz M, Hartwich A, Rehfeld JF, Hahn EG. COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. Dig Dis Sci 2003;48:2005-2017.","DOI":"10.1023\/A:1026387908165"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-3410.","DOI":"10.1074\/jbc.272.6.3406"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH, Wu T. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J Biol Chem 2002;277:33153-33163.","DOI":"10.1074\/jbc.M200246200"},{"key":"ref39","unstructured":"Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001;61:497-503."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Röcken C, Malfertheiner P, Farrell GC. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006;43:134-143.","DOI":"10.1002\/hep.20994"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Shaik MS, Chatterjee A, Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma. Clin Cancer Res 2004;10:1521-1529.","DOI":"10.1158\/1078-0432.CCR-0902-03"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 2006;118:396-404.","DOI":"10.1002\/ijc.21325"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i22\/2731.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T21:58:40Z","timestamp":1558389520000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i22\/2731.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":42,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.15.2731","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}